Inclusion Criteria:  Signed Informed Consent Diagnosis of COPD/emphysema Age 40 to 75 years Body Mass Index (BMI) less than 30 kg/m2 6-minute walk Distance between 100 meters and 500 meters at baseline exam Stable disease with less than 10 mg prednisone (or equivalent) daily Non-smoking for 4 months prior to screening interview FEV1 between 15% and 50% of predicted value at baseline exam FEV1/Forced Vital Capacity (FVC) < 70% RV > 175% mMRC score ≥ 2  Exclusion Criteria:  Currently participating in another clinical study Women of child-bearing potential More than 2 COPD exacerbation episodes requiring hospitalization in the last year at screening Any COPD exacerbations within 6 weeks of planned intervention Two or more instances of pneumonia episodes in the last year at screening Clinically significant mucus production or chronic bronchitis Myocardial Infarction or unstable / uncontrolled congestive heart failure within 6 months of screening Prior lung transplant, Lung Volume Reduction Surgery (LVRS), bullectomy or lobectomy Clinically significant bronchiectasis Unable to safely discontinue anti-coagulants or platelet activity inhibitors for 7 days Uncontrolled pulmonary hypertension (systolic pulmonary arterial pressure > 45 mm Hg) or evidence or history of cor pulmonale as determined by recent echocardiogram (completed within the last 3 months prior to screening visit) Suspected pulmonary nodule or lung cancer  High Resolution Computed Tomography (HRCT) collected per CT scanning protocol within the last 6 months of screening date and evaluated by clinical site personnel using 3D segmentation software shows:  Large bullae encompassing greater than 30% of either lung Insufficient landmarks to evaluate the CT study using the software as it is intended All lobes are less than 25% parenchyma diseased (< -950 HU) Any cardiac comorbidity which the PI believes would compromise the safety of the patient after an IAB implant Total Lung Capacity (TLC) < 100% predicted at screening Diffusing Capacity of Carbon Monoxide (DLCO) < 15% or > 50% of predicted value at screening Partial pressure of carbon dioxide (PaCO2) > 50 mm Hg or Denver scale greater than 55 mm Hg on room air at screening Partial pressure of oxygen (PaO2) < 45 mm Hg or Denver scale less than 30 mm Hg on room air at screening Plasma cotinine level > 13.7 ng/ml or carboxyhemoglobin (arterial or ear lobe capillary) > 2.5% at screening Any other conditions, which, in the opinion of the Investigator, would make the patient unsuitable for inclusion, or could interfere with the patient participating in or completing the study